New treatment option for people with branch retinal vein occlusions
People with macular edema due to branch retinal vein occlusion (BRVO) now have another treatment option following the PBS listing of Eylea (aflibercept) for this indication on 1 December 2016. Eylea had previously been listed for central retinal vein occlusions (CRVO).
The treatment is given as a series of injections into the eye.
Retinal vein occlusions occur when a vein in the retina becomes constricted or blocked, with a blood clot forming at the blockage. The reduction of blood flow then leads to a loss of oxygenation (ischaemia) in parts of the retina. This can stimulate the growth of new blood vessels, but unfortunately these new vessels may have thin walls and leak blood or fluid, leading to swelling of the retina and potentially vision impairment. Injections are generally very successful in controlling the formation of the new vessels, reducing swelling and preserving vision.
For a factsheet on retinal vein occlusions, call the Foundation on 1800 111 709.
20 December 2016